Solx Inc. raised $3.7 million in equity financing, according to a federal Securities & Exchange Commission filing.
The funding represents just over half of an offering from which the company hopes to bring in $7.2 million.
Solx, which is developing a laser treatment for glaucoma, won 510(k) clearance from the Food & Drug Administration in September 2008 for its 790 Titanium Sapphire laser device, which uses a gold shunt to relieve intraocular pressure while preserving trabecular tissue.
The company was hatched from the incubator program at Boston University’s Photonics Center. It’s a former subsidiary of San Diego-based ophthalmic device maker TearLab (NSDQ:TEAR), formerly known as OccuLogix Inc. OccuLogix and Solx parted ways in Dec. 2007.